329 related articles for article (PubMed ID: 32723974)
1. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma.
Luo R; Song J; Xiao X; Xie Z; Zhao Z; Zhang W; Miao S; Tang Y; Ran L
Aging (Albany NY); 2020 Jul; 12(14):14649-14676. PubMed ID: 32723974
[TBL] [Abstract][Full Text] [Related]
2. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.
Liu Z; Lin G; Yan Z; Li L; Wu X; Shi J; He J; Zhao L; Liang H; Wang W
Front Immunol; 2022; 13():989275. PubMed ID: 36238300
[TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
4. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Meng G; Liu X; Ma T; Lv D; Sun G
PLoS One; 2022; 17(2):e0263629. PubMed ID: 35113949
[TBL] [Abstract][Full Text] [Related]
6. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients.
Li H; Ma ZL; Li B; Pan YJ; Xiang JQ; Zhang YW; Sun YH; Hou T; Lizaso A; Chen Y; Li X; Hu H
Cancer Med; 2021 Dec; 10(23):8377-8386. PubMed ID: 34664796
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer.
Cai L; Bai H; Duan J; Wang Z; Gao S; Wang D; Wang S; Jiang J; Han J; Tian Y; Zhang X; Ye H; Li M; Huang B; He J; Wang J
J Immunother Cancer; 2019 Jul; 7(1):198. PubMed ID: 31349879
[TBL] [Abstract][Full Text] [Related]
8. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
9. Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.
Zhao X; Yang M; Fan J; Wang M; Wang Y; Qin N; Zhu M; Jiang Y; Gorlova OY; Gorlov IP; Albanes D; Lam S; Tardón A; Chen C; Goodman GE; Bojesen SE; Landi MT; Johansson M; Risch A; Wichmann HE; Bickeböller H; Christiani DC; Rennert G; Arnold SM; Brennan P; Field JK; Shete S; Le Marchand L; Liu G; Hung RJ; Andrew AS; Kiemeney LA; Zienolddiny S; Grankvist K; Johansson M; Caporaso NE; Woll PJ; Lazarus P; Schabath MB; Aldrich MC; Patel AV; Davies MPA; Ma H; Jin G; Hu Z; Amos CI; Shen H; Dai J
Cancer; 2024 Mar; 130(6):913-926. PubMed ID: 38055287
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognostic signature of non-small cell lung cancer based on TCGA methylation data.
Wang Y; Wang Y; Wang Y; Zhang Y
Sci Rep; 2020 May; 10(1):8575. PubMed ID: 32444802
[TBL] [Abstract][Full Text] [Related]
11. Methylation markers of early-stage non-small cell lung cancer.
Lokk K; Vooder T; Kolde R; Välk K; Võsa U; Roosipuu R; Milani L; Fischer K; Koltsina M; Urgard E; Annilo T; Metspalu A; Tõnisson N
PLoS One; 2012; 7(6):e39813. PubMed ID: 22768131
[TBL] [Abstract][Full Text] [Related]
12. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
[TBL] [Abstract][Full Text] [Related]
13. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
14. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
16. Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
Li X; Wang R; Wang S; Wang L; Yu J
Front Immunol; 2022; 13():989968. PubMed ID: 36389757
[TBL] [Abstract][Full Text] [Related]
17. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
18. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
[No Abstract] [Full Text] [Related]
19. Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer.
Xu D; Li J; Wang D; Zhou L; Jin J; Wang Y
Crit Rev Oncol Hematol; 2022 Jan; 169():103573. PubMed ID: 34933103
[TBL] [Abstract][Full Text] [Related]
20. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
Pan D; Hu AY; Antonia SJ; Li CY
J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
